11月25日晚间阳光诺和(688621)公告，根据公司的整体经营规划，全资子公司北京诺和德美医药技术有 限公司（下称"诺和德美"）与北京中健培联医学研究院（普通合伙）（下称"中健培联"）签署《上海美 速科用数据有限公司股权转让协议》，按照实缴出资比例，诺和德美以200万元现金对价将其持有的上 海美速科用数据有限公司（下称"美速科用"）70%的股权转让给中健培联，上海诺和美创医药研究合伙 企业（有限合伙）以0万元现金对价将其持有的美速科用30%的股权转让给中健培联。交易完成后，诺 和德美不再持有美速科用股权，美速科用不再纳入公司合并报表范围。 公告显示，鉴于美速科用为已结项募投项目"临床试验服务平台建设项目"的实施主体之一，故本次交易 同时涉及部分募投项目转让。 美速科用为阳光诺和早前募投项目"临床试验服务平台建设项目"的实施主体，目前该项目已建设完毕并 达到可使用状态，已予以结项。美速科用累计取得募集资金1728.87万元（含利息9856.53元），其中450 万元为诺和德美支付给美速科用的注册资金。 阳光诺和表示，美速科用上述募集资金中剩余1277.89万元已归还至阳光诺和募集资金专户，未来将用 于投入募投 ...

Core Points - The company announced a change in the implementation location of a previously approved fundraising project from "Dongguan City Tangxia Town" to "Dongguan City Qingxi Town Galaxy Industrial Zone" [1] - The change will not affect the purpose or implementation method of the raised funds, nor will it negatively impact the company's normal production and business development [1] - The company has completed the business registration change and obtained a new business license for its Qingxi branch [1]

Core Viewpoint - The company, Andavil (300719.SZ), has responded to the Shenzhen Stock Exchange's second round of inquiry regarding changes in its fundraising projects and whether the new financing involves duplicate construction, asserting that the adjustments were primarily due to external environmental changes and that the new projects significantly differ from previous ones [1] Group 1: Fundraising Project Adjustments - The adjustments to previous fundraising projects were influenced by external factors such as tightened repair authorizations from international OEM manufacturers, delays in the domestic large aircraft industrialization process, and a contraction in civil aviation market demand [1] - The company emphasized that all previous fundraising capital was ultimately directed towards its main business and not used for non-core business areas [1] Group 2: New Financing Projects - The new fundraising project, "Aviation Onboard Equipment and Aviation Maintenance Industrial Base Project," while overlapping in some business areas with previous projects, focuses on improving existing maintenance efficiency, expanding the range of new part numbers, and increasing the production capacity of aviation kitchen and bathroom systems based on the demand for domestically produced aircraft [1]

Core Viewpoint - Anjiu Food Group Co., Ltd. has announced a change in its fundraising project, reallocating 361 million yuan from its original technology upgrade projects to a new baking project, reflecting a strategic shift in response to market changes [1][2]. Group 1: Fundraising and Project Changes - The company plans to redirect 361 million yuan of its previously raised funds to the Dingyifeng Baking Project, which involves the construction of a new baking facility [1][2]. - The original fundraising amount was approximately 5.67 billion yuan, with a net amount of about 5.63 billion yuan after expenses. As of September 23, 2025, the company has invested 4.34 billion yuan, achieving a progress rate of 76.99% [1][2]. Group 2: New Baking Project Details - The Dingyifeng Baking Project will produce various baked goods, with a designed daily capacity of 67.42 tons. The total investment for the project is 410 million yuan, with 361 million yuan sourced from the fundraising [2][3]. - The project is expected to generate annual revenue of approximately 613.39 million yuan and a profit of about 67.83 million yuan, with an internal rate of return of 10.38% and a payback period of 8.05 years [3]. Group 3: Market Context and Challenges - The frozen food industry is experiencing intense competition, with a significant increase in the number of enterprises in the prepared dish sector, leading to aggressive price wars [4]. - In the first half of 2025, the company reported revenue of 7.60 billion yuan, a slight increase of 0.8%, but a notable decline in net profit by 15.79%, marking the first negative growth in mid-year net profit since its listing [3][4].

ANJOY FOODS GROUP CO., LTD. 安井食品集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2648） 關於變更非公開發行股票部分募投項目的公告 茲提述安井食品集團股份有限公司（「公司」）日期為2025年6月25日的招股章程 「歷史、發展及公司架構－2022年的A股非公開發行」一節，內容有關公司於2022 年非公開發行A股，募集的所得款項淨額為人民幣5,634,574,077.18元。 一、變更募投項目的概述 （一）募集資金基本情況 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 經公司第四屆董事會第十七次會議、2020年年度股東大會審議通過，並 經中國證券監督管理委員會《關於核准福建安井食品股份有限公司非公 開發行股票的批覆》（證監許可[2021]3419號）核准，公司通過非公開發 行股票方式向特定投資者發行48,884,872股人民幣普通股（A股），發行價 格為人民幣116.08元╱股，募集資金總額為 ...

Group 1 - The company held its 11th meeting of the 3rd Board of Directors on September 17, 2025, via communication, with all 9 directors present [2][4] - The Board approved the proposal to change part of the fundraising investment project and to pay registered capital to a subsidiary for project implementation [3][22] - The proposal will be submitted to the company's third extraordinary general meeting of shareholders for approval [6][22] Group 2 - The Supervisory Board also held its 9th meeting on September 17, 2025, with all 5 supervisors present, and approved the same proposal [12][14] - The company plans to change the investment project from the original Lishui City Hangli Thermal Power Project to the new Hubei Xiaochi Binjiang New District Combined Heat and Power Project [18][25] - The amount of funds to be redirected is approximately 67.07 million yuan, which will be used for the new project [18][21] Group 3 - The new project is expected to have a construction period of 18 months and will gradually generate revenue upon completion [19][31] - The total investment for the new project is estimated at around 670 million yuan, with the company contributing 67.07 million yuan from the redirected funds [21][26] - The project aligns with national and local industrial policies and is expected to support local economic development [27][28] Group 4 - The company has obtained necessary approvals for the new project, including environmental impact assessments and construction permits [38] - The project is anticipated to create job opportunities and contribute positively to the local economy [28][30] - The internal rate of return after tax for the project is projected to be 7.13%, with a payback period of 11.9 years [31]

Group 1 - The company is holding its second extraordinary general meeting of shareholders on September 12, 2025, to ensure the rights of all shareholders and maintain order during the meeting [1][3] - The meeting will include a combination of on-site and online voting, with results to be announced after the voting process [2][3] - Shareholders and their representatives have the right to speak, inquire, and vote during the meeting, but must adhere to the established rules and procedures [2][3] Group 2 - The company plans to terminate certain fundraising projects and allocate the remaining funds to new projects, specifically reallocating 68.2 million yuan to the "Changzhou Production Base Automation Upgrade Project" [6][7] - The decision to terminate these projects is based on changes in market conditions and the company's operational strategy, ensuring compliance with relevant laws and regulations [6][7] - The company will ensure the legal and effective use of the remaining funds and will not engage in related party transactions regarding this change in fundraising usage [7]

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the utilization of funds by Zhejiang Fulai New Materials Co., Ltd. as of June 30, 2025, confirming compliance with regulatory requirements and detailing the financial status of previous fundraising efforts. Group 1: Fundraising Overview - The company raised a total of RMB 612.90 million from its initial public offering (IPO) in 2021, with a net amount of RMB 530.63 million after deducting underwriting fees and other expenses [4][5]. - In 2023, the company issued convertible bonds, raising RMB 429.02 million, with a net amount of RMB 415.95 million after expenses [6][9]. Group 2: Fund Utilization - As of June 30, 2025, the company has utilized RMB 504.07 million of the raised funds, with RMB 12.65 million remaining in bank accounts [5][10]. - The company temporarily used RMB 50 million of idle funds to supplement working capital [20][24]. Group 3: Changes in Fund Allocation - The company approved changes to the allocation of funds for the "Functional Coating Composite Material Production Base and R&D Center Headquarters" project, reallocating 37.69% of the total funds raised [11]. - The company also transferred assets and liabilities from its subsidiary to optimize its organizational structure and improve operational efficiency [12]. Group 4: Financial Performance and Returns - The company reported a total interest income and returns from structured deposits amounting to RMB 2.47 million from the IPO funds [5][10]. - The actual investment in the "New Environmental Pre-coating Functional Material Construction Project" was RMB 31.23 million, which is lower than the committed amount due to market conditions and project delays [15][18]. Group 5: Idle Fund Management - The company has engaged in cash management by investing idle funds in low-risk, short-term financial products, achieving returns of RMB 1.06 million in 2021 and RMB 0.166 million in 2022 [20][22]. - As of June 30, 2025, all structured deposit products purchased with idle funds have been redeemed [25].

Fundraising and Storage Situation - The company raised a total of RMB 61,290.00 million from its initial public offering (IPO) in 2021, with a net amount of RMB 53,063.13 million after deducting fees [1][2] - As of June 30, 2025, the remaining balance of the previous fundraising is RMB 126.49 million, with RMB 5,000.00 million used for working capital [1][2] - The company raised RMB 42,901.80 million from the issuance of convertible bonds in 2023, with a net amount of RMB 41,589.49 million after deducting fees [1][2] Fund Usage - The company has utilized RMB 50,406.72 million of the funds raised from the 2021 IPO, with a remaining balance of RMB 5,126.49 million, accounting for 9.66% of the net amount [1][12] - The company plans to continue using the remaining funds for investment projects [12] - The company has used RMB 31,225.80 million of the funds raised from the 2023 convertible bond issuance, with a remaining balance of RMB 11,747.47 million, accounting for 28.25% of the net amount [12] Changes in Fund Usage - The company has approved a change in the use of RMB 20,000.00 million from the 2021 IPO funds to invest in a new materials project in Yantai, which represents 37.69% of the total funds raised [1][2] - The company has also approved changes to the implementation location and extended the deadline for the "New Environmental Pre-coating Functional Materials Construction Project" funded by the 2023 convertible bonds [1][2] Investment Efficiency and Returns - The actual investment amount for the "Functional Coating Composite Material Production Base and R&D Center Headquarters" project is RMB 50,406.72 million, with a shortfall of RMB 2,656.41 million compared to the committed amount due to interest income and bank fees [5] - The "New Environmental Pre-coating Functional Materials Construction Project" has an actual investment of RMB 31,225.80 million, with a shortfall of RMB 10,363.69 million as the project is still under construction [5] Idle Fund Management - The company has used idle funds from the 2021 IPO to temporarily supplement working capital, amounting to RMB 5,000 million [7][10] - The company has also engaged in financial management of idle funds, purchasing low-risk, short-term financial products, with a total of RMB 53,500.00 million in structured deposits and RMB 1,064.91 million in returns in 2021 [8][9]

Core Viewpoint - The report provides a detailed account of the fundraising activities and the usage of funds by 博瑞生物医药 (Suzhou) Co., Ltd. as of June 30, 2025, highlighting the amounts raised, their allocation, and the management of these funds [1][2][3]. Fundraising Overview - The company raised a total of RMB 521.11 million from its initial public offering (IPO) in 2019, with a net amount of RMB 439.98 million after deducting various fees [1]. - In 2022, the company issued convertible bonds amounting to RMB 465 million, resulting in a net amount of RMB 456.83 million after fees [2]. - The company also raised RMB 226.61 million through a private placement of shares in November 2022, with the net amount after fees not specified [2]. Fund Management - The company established a dedicated account for managing the raised funds, ensuring that the funds are used specifically for their intended purposes [3]. - A tripartite supervision agreement was signed with the underwriter and banks to oversee the management of the funds [3]. Fund Usage and Balance - As of June 30, 2025, the total amount of funds used from the IPO was RMB 455.75 million, with a remaining balance of RMB 0.00 million [5]. - For the convertible bonds, RMB 466.75 million was used, leaving no remaining balance [5]. - From the private placement, RMB 188.74 million was utilized, with a remaining balance of RMB 3.64 million [13]. Project Adjustments - The company did not make any adjustments to the investment amounts for the projects funded by the IPO as of June 30, 2025 [5]. - The overseas high-end formulation drug production project was delayed, with the expected completion date pushed from December 2021 to June 2023 due to various factors including the pandemic [5]. - The company has also changed the implementation entities for some projects to improve management efficiency [5]. Temporary Idle Funds - The company has not used idle funds to temporarily supplement working capital as of June 30, 2025 [8]. - The company has engaged in cash management for temporarily idle funds, generating a total return of RMB 15.62 million from such activities [10][12].